Literature DB >> 25225838

Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Lisa G Rider1, Katalin Dankó, Frederick W Miller.   

Abstract

PURPOSE OF REVIEW: Clinical registries and biorepositories have proven extremely useful in many studies of diseases, especially rare diseases. Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have benefited from individual researchers' collections of cohorts of patients. Major efforts are being made to establish large registries and biorepositories that will allow many additional studies to be performed that were not possible before. Here, we describe the registries developed by investigators and patient support groups that are currently available for collaborative research purposes. RECENT
FINDINGS: We have identified 46 myositis research registries, including many with biorepositories, which have been developed for a wide variety of purposes and have resulted in great advances in understanding the range of phenotypes, clinical presentations, risk factors, pathogenic mechanisms, outcome assessment, therapeutic responses, and prognoses. These are now available for collaborative use to undertake additional studies. Two myositis patient registries have been developed for research, and myositis patient support groups maintain demographic registries with large numbers of patients available to be contacted for potential research participation.
SUMMARY: Investigator-initiated myositis research registries and biorepositories have proven extremely useful in understanding many aspects of these rare and diverse autoimmune diseases. These registries and biorepositories, in addition to those developed by myositis patient support groups, deserve continued support to maintain the momentum in this field as they offer major opportunities to improve understanding of the pathogenesis and treatment of these diseases in cost-effective ways.

Entities:  

Mesh:

Year:  2014        PMID: 25225838      PMCID: PMC5081267          DOI: 10.1097/BOR.0000000000000119

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  157 in total

1.  Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  A M Huber; J E Hicks; P A Lachenbruch; M D Perez; L S Zemel; R M Rennebohm; C A Wallace; C B Lindsley; M H Passo; S H Ballinger; S L Bowyer; A M Reed; P H White; I M Katona; F W Miller; L G Rider; B M Feldman
Journal:  J Rheumatol       Date:  2001-05       Impact factor: 4.666

2.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

Authors:  Rita K Bode; Marisa S Klein-Gitelman; Michael L Miller; Toula S Lechman; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-02-15

3.  Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele.

Authors:  T O Fedczyna; J Lutz; L M Pachman
Journal:  Clin Immunol       Date:  2001-08       Impact factor: 3.969

4.  Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality.

Authors:  S M Sultan; Y Ioannou; K Moss; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2002-01       Impact factor: 7.580

5.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry.

Authors:  Eduardo P Mendez; Rebecca Lipton; Rosalind Ramsey-Goldman; Phil Roettcher; Susan Bowyer; Alan Dyer; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-06-15

6.  Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Authors:  Zivana Tezak; Eric P Hoffman; Jennica L Lutz; Tamara O Fedczyna; Dietrich Stephan; Eric G Bremer; Irina Krasnoselska-Riz; Ajit Kumar; Lauren M Pachman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

7.  TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

Authors:  L M Pachman; M R Liotta-Davis; D K Hong; T R Kinsella; E P Mendez; J M Kinder; E H Chen
Journal:  Arthritis Rheum       Date:  2000-10

Review 8.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

9.  Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

Authors:  Adam M Huber; Brian M Feldman; Robert M Rennebohm; Jeanne E Hicks; Carol B Lindsley; Maria D Perez; Lawrence S Zemel; Carol A Wallace; Susan H Ballinger; Murray H Passo; Ann M Reed; Ronald M Summers; Patience H White; Ildy M Katona; Frederick W Miller; Peter A Lachenbruch; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2004-05

10.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

View more
  7 in total

Review 1.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

2.  Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies.

Authors:  Michal Feldon; Payam Noroozi Farhadi; Hermine I Brunner; Lukasz Itert; Bob Goldberg; Abdullah Faiq; Jesse Wilkerson; Kathryn M Rose; Lisa G Rider; Frederick W Miller; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

3.  Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.

Authors:  Jessica Neely; Kaveh Ardalan; Adam Huber; Susan Kim
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-19       Impact factor: 3.413

Review 4.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

5.  Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

Authors:  Liza J McCann; Clarissa A Pilkington; Adam M Huber; Angelo Ravelli; Duncan Appelbe; Jamie J Kirkham; Paula R Williamson; Amita Aggarwal; Lisa Christopher-Stine; Tamas Constantin; Brian M Feldman; Ingrid Lundberg; Sue Maillard; Pernille Mathiesen; Ruth Murphy; Lauren M Pachman; Ann M Reed; Lisa G Rider; Annet van Royen-Kerkof; Ricardo Russo; Stefan Spinty; Lucy R Wedderburn; Michael W Beresford
Journal:  Ann Rheum Dis       Date:  2017-10-30       Impact factor: 19.103

Review 6.  B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.

Authors:  Meredyth G Ll Wilkinson; Elizabeth C Rosser
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

7.  The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Authors:  James B Lilleker; Jiri Vencovsky; Guochun Wang; Lucy R Wedderburn; Louise Pyndt Diederichsen; Jens Schmidt; Paula Oakley; Olivier Benveniste; Maria Giovanna Danieli; Katalin Danko; Nguyen Thi Phuong Thuy; Monica Vazquez-Del Mercado; Helena Andersson; Boel De Paepe; Jan L deBleecker; Britta Maurer; Liza J McCann; Nicolo Pipitone; Neil McHugh; Zoe E Betteridge; Paul New; Robert G Cooper; William E Ollier; Janine A Lamb; Niels Steen Krogh; Ingrid E Lundberg; Hector Chinoy
Journal:  Ann Rheum Dis       Date:  2017-08-30       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.